Simcere Pharmaceutical Group (FRA:S2P) Insider Ownership: 0.00 % (As of Sep. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S2P Simcere Pharmaceutical Group Ltd FRA:S2P
95 GF Score
Price €1.25
GF Value €1.21
Valuation Fairly Valued
View Full Analysis

What is Simcere Pharmaceutical Group Insider Ownership?

Simcere Pharmaceutical Group FRA:S2P -6.72% 95 Insider Ownership is 0.00 % as of Sep. 08, 2026. GuruFocus rates FRA:S2P with a GF Score™ of 95/100 and a GF Value™ of €1.21 (Fairly Valued).

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Simcere Pharmaceutical Group's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Simcere Pharmaceutical Group's Institutional Ownership is 12.80%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Simcere Pharmaceutical Group's Float Percentage Of Total Shares Outstanding is 0.00%.

Simcere Pharmaceutical Group Insider Ownership Historical Data

* Premium members only.

The historical data trend for Simcere Pharmaceutical Group's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Insider Ownership Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:S2P
95GF Score
Simcere Pharmaceutical Group Ltd FRA:S2P
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simcere Pharmaceutical Group Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Simcere Pharmaceutical Group (FRA:S2P) has a Insider Ownership of 0.00 % as of Sep. 08, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Insider Ownership too high?
Simcere Pharmaceutical Group's current Insider Ownership is 0.00 %. Overall, Simcere Pharmaceutical Group has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Insider Ownership compare to ZTS?
Simcere Pharmaceutical Group's Insider Ownership of 0.00 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (FRA:S2P) is currently considered Fairly Valued. The stock's GF Value™ is €1.21, compared to a current price of €1.25 — trading 3.3% above its estimated fair value. The current Insider Ownership is 0.00 %. Simcere Pharmaceutical Group's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Simcere Pharmaceutical Group (FRA:S2P), the current Insider Ownership is 0.00 % as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.25 is trading 3.3% above its estimated GF Value™ of €1.21. GuruFocus considers Simcere Pharmaceutical Group to be Fairly Valued.

Key valuation signals for FRA:S2P:

  • Insider Ownership: 0.00 %
  • GF Value™: €1.21 vs. price of €1.25 (3.3% above fair value)
  • GF Score™: 95/100

No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong KongS2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
95GF Score

Get the complete analysis for FRA:S2P

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.25
Price
€1.21
GF Value